INTEGRATED CORE STRATEGIES (US) LLC - 31 Dec 2025 SCHEDULE 13G/A Report for BioXcel Therapeutics, Inc. Common Stock, par value $0.001 per share (BTAI)

Filing Manager
INTEGRATED CORE STRATEGIES (US) LLC
Reporting Manager
Millennium Management LLC
Security
BioXcel Therapeutics, Inc. Common Stock, par value $0.001 per share
Symbol
BTAI
Shares outstanding
21,847,524 shares
Disclosed Ownership
1,835,192 shares
Ownership
8.4%
Form type
SCHEDULE 13G/A
Filing time
09 Feb 2026, 16:13:17 UTC
Date of event
31 Dec 2025
Previous filing
01 Oct 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"INTEGRATED CORE STRATEGIES (US) LLC disclosed 8.4% ownership in BioXcel Therapeutics, Inc. Common Stock, par value $0.001 per share (BTAI) on 31 Dec 2025."

Quick Takeaways

  • INTEGRATED CORE STRATEGIES (US) LLC filed SCHEDULE 13G/A for BioXcel Therapeutics, Inc. Common Stock, par value $0.001 per share (BTAI).
  • Disclosed ownership: 8.4%.
  • Date of event: 31 Dec 2025.

What Changed

  • Previous schedule filing date: 01 Oct 2025.
  • Current filing was accepted on 09 Feb 2026, 16:13.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Official SEC Source

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (4)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Integrated Core Strategies (US) LLC 8.4% 1,833,717 0 1,833,717 /s/ Gil Raviv Gil Raviv, Global General Counsel
Millennium Management LLC 8.4% 1,835,192 0 1,835,192 /s/ Gil Raviv Gil Raviv, Global General Counsel
Millennium Group Management LLC 8.4% 1,835,192 0 1,835,192 /s/ Gil Raviv Gil Raviv, Global General Counsel
Israel A. Englander 8.4% 1,835,192 0 1,835,192 /s/ Israel A. Englander Israel A. Englander

Sponsored